Bdnf mRNA‐LNP Drives Nasal Epithelial BDNF Production and Improves Cognition in Aged and Alzheimer's Disease Mouse Models

Messenger RNA (mRNA) therapeutics have rapidly emerged as a transformative approach for treating a range of health challenges. Accelerated by the success of mRNA-lipid nanoparticle (LNP) vaccines during the COVID-19 pandemic, this platform holds promise beyond immunisation for the transient expression of therapeutic proteins in targeted tissues. Despite this promise, non-invasive delivery of mRNA-encoded cargo to the brain remains a challenge, as most peptide drugs do not pass the blood-brain barrier. Here, we present the development of an intranasal mRNA-LNP therapeutic that drives production of neurotrophic factors in the nasal epithelium and delivery of the encoded protein to the brain. As a proof of concept, we demonstrate that intranasal delivery of mRNA encoding the neurogenic factor BDNF (Brain Derived Neurotrophic Factor) enhances memory performance in both aged mice and a transgenic mouse model of Alzheimer's disease. This approach offers a promising platform for delivering therapeutic proteins to the brain and opens new avenues for treating age-related and neurodegenerative disorders.

Authors

Institutions

Publication Details

Journal
Advanced Science
Published
2026-11-18
DOI
https://doi.org/10.1002/advs.78225
Primary Topic
RNA Interference and Gene Delivery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Bdnf mRNA‐LNP Drives Nasal Epithelial BDNF Production and Improves Cognition in Aged and Alzheimer's Disease Mouse Models

G. Gregory Neely, Hannah A. Scarborough, Lipin Loo, Maria Bergamasco et al.
4 links
Advanced Science
RNA Interference and Gene Delivery
article

Bdnf mRNA‐LNP Drives Nasal Epithelial BDNF Production and Improves Cognition in Aged and Alzheimer's Disease Mouse Models

G. Gregory Neely, Hannah A. Scarborough, Lipin Loo, Maria Bergamasco, R. M. Damian Holsinger, Scott B. Cohen, Teleri Clark, Kazuma Fujikake, Rebecca Carr, Anna Ponta
article en

Abstract

Messenger RNA (mRNA) therapeutics have rapidly emerged as a transformative approach for treating a range of health challenges. Accelerated by the success of mRNA-lipid nanoparticle (LNP) vaccines during the COVID-19 pandemic, this platform holds promise beyond immunisation for the transient expression of therapeutic proteins in targeted tissues. Despite this promise, non-invasive delivery of mRNA-encoded cargo to the brain remains a challenge, as most peptide drugs do not pass the blood-brain barrier. Here, we present the development of an intranasal mRNA-LNP therapeutic that drives production of neurotrophic factors in the nasal epithelium and delivery of the encoded protein to the brain. As a proof of concept, we demonstrate that intranasal delivery of mRNA encoding the neurogenic factor BDNF (Brain Derived Neurotrophic Factor) enhances memory performance in both aged mice and a transgenic mouse model of Alzheimer's disease. This approach offers a promising platform for delivering therapeutic proteins to the brain and opens new avenues for treating age-related and neurodegenerative disorders.

Advanced Science
The University of Sydney (AU), Children's Medical Research Institute (AU), UNSW Sydney (AU), Neuroscience Research Australia (AU)
Good health and well-being
RNA Interference and Gene Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon